Whitehawk Therapeutics, Inc. (WHWK) stock
WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.08+0.07 (+2.33%)
Close on Nov 17, 2026Market cap $175.59MP/E –Yield –
Whitehawk Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Whitehawk Therapeutics's gross margin for the twelve months ending Dec 31, 2025 was 89.4%. For fiscal 2025 it was 89.4%, against 88.4% the year before. The highest annual figure on record is 100.0% in fiscal 2021.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 89.4% | +1.0 |
| FY2024 | Dec 31, 2024 | 88.4% | −0.1 |
| FY2023 | Dec 31, 2023 | 88.5% | −2.8 |
| FY2022 | Dec 31, 2022 | 91.2% | −8.8 |
| FY2021 | Dec 31, 2021 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | 89.4% | +1.5 |
| Q4 FY2024 | Dec 31, 2024 | 89.1% | +3.7 |
| Q3 FY2024 | Sep 30, 2024 | 88.9% | +0.5 |
| Q2 FY2024 | Jun 30, 2024 | 87.4% | −2.0 |
| Q1 FY2024 | Mar 31, 2024 | 87.8% | −3.2 |
| Q4 FY2023 | Dec 31, 2023 | 85.3% | −10.4 |
| Q3 FY2023 | Sep 30, 2023 | 88.3% | +2.3 |
| Q2 FY2023 | Jun 30, 2023 | 89.4% | −0.7 |
| Q1 FY2023 | Mar 31, 2023 | 91.0% | −1.3 |
| Q4 FY2022 | Dec 31, 2022 | 95.8% | −4.2 |
| Q3 FY2022 | Sep 30, 2022 | 86.0% | – |
| Q2 FY2022 | Jun 30, 2022 | 90.1% | – |
| Q1 FY2022 | Mar 31, 2022 | 92.2% | – |
| Q4 FY2021 | Dec 31, 2021 | 100.0% | – |
See a number that looks wrong?